Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance

Overview

• Niagen Bioscience Q3 net sales rise 33%, beating analyst expectations

• Adjusted EBITDA for Q3 increases 120%, reflecting improved operational performance

• Company reaffirms full-year net sales growth outlook of 25% to 30%

Outlook

• Niagen Bioscience reaffirms 2025 net sales growth of 25% to 30% y-o-y

• Company expects 2025 gross margin to improve from 61.8% in 2024

• General and administrative expenses projected at $8.0 to $9.0 mln for 2025

Result Drivers

• TRU NIAGEN SALES - Growth in net sales driven by a 44% increase in Tru Niagen sales, supported by strong e-commerce performance

• GROSS MARGIN IMPROVEMENT - Gross margin increased by 100 bps to 64.5% due to changes in product mix and lower-cost inventory purchases

• DISTRIBUTION EXPANSION - Expanded distribution network for Niagen Plus IV and injectable therapies to over 1,000 clinics, including iCRYO locations

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Niagen Bioscience Inc is $16.00, about 54.8% above its November 3 closing price of $7.23

• The stock recently traded at 29 times the next 12-month earnings vs. a P/E of 48 three months ago

Press Release: ID:nBw1Sp4zda

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)